Drug Database
PA

parathyroid hormone (Natpara / NPSP558 / SHP634)

✓ Approved

AstraZeneca UK Limited · PTH1R · 重组蛋白

什么是 parathyroid hormone?

parathyroid hormone 是一种重组蛋白,由AstraZeneca UK Limited研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Natpara, NPSP558, SHP634
公司AstraZeneca UK Limited
药物类别重组蛋白
分子靶点PTH1R
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

parathyroid hormone 作用于 1 个分子靶点:

PTH1Rparathyroid hormone 1 receptor (PTHR, EKNS)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

parathyroid hormone 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Endocrine disordersHypoparathyroidism✓ Approved
Musculoskeletal and connective tissue disordersOsteoporosis✓ Approved

相关研究文献

PubMedJournal of medical case reports2026-11-19

Rapid progression of myocardial calcification in a patient presenting with hypercalcemia of unidentified etiology: a case report.

Hirai Shota S, Nishigaito Toshiya T, Mitsumoto Kensuke K, Mizumoto Aya A et al.

Myocardial calcification is an uncommon but clinically important finding that may result in severe cardiac dysfunction. It is generally classified as metastatic calcification triggered by an elevated serum calcium-phosphate product or dystrophic calcification occurring at sites of prior inflammatory or ischemic injury. There are few reports describing dynamic changes in myocardial calcification among patients with hypercalcemia. In addition, hypercalcemia with an unidentified cause has rarely been reported. We encountered a fatal case that developed both metastatic and dystrophic myocardial calcification. This case may contribute to a better understanding of the potential cardiac complications of severe hypercalcemia.Affiliations: Journal instruction requires a city and country for affiliations; however, these are missing in affiliation [2, 3]. Please verify if the provided city and country are correct and amend if necessary.All authors' affiliation addresses are Osaka, Japan. A 57-year-old Japanese woman with a history of asthma presented with nausea and fatigue. She had severe hypercalcemia with acute kidney injury and marked eosinophilia. Intact parathyroid hormone was suppressed (11 pg/mL), with normal parathyroid hormone-related protein and vitamin D metabolites. Fractional excretion of calcium was elevated to 12%. Imaging studies, bone marrow examination, and renal biopsy did not identify a definitive etiology. She was diagnosed with severe hypercalcemia of unidentified etiology complicated by acute kidney injury and eosinophilia. Despite intravenous fluids, calcitonin, and denosumab followed by hemodialysis, she developed progressive respiratory failure and circulatory collapse with myocardial injury and coronary microvascular dysfunction, and serial CT showed new myocardial calcification from day 9 with rapid diffuse progression. She died 22 days after admission despite extracorporeal circulatory support, and autopsy revealed extensive multi-organ calcification including the heart and lungs. Severe hypercalcemia of unidentified etiology can be complicated by extensive myocardial calcification. Ectopic calcification initially induced by hypercalcemia may have been influenced by inflammatory conditions such as eosinophilia. In addition, subsequent myocardial injury may accelerate dystrophic calcification. Clinicians should be aware of the risk of early and progressive cardiac involvement in patients with hypercalcemia, particularly in the presence of inflammatory conditions.

PMID 43053195
阅读全文 →
PubMedInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026-11-19

Response: Association between type and duration of menopausal hormone therapy and endometrial cancer risk: A population-based study.

Yoon Sang-Hee SH, Yuk Jin-Sung JS

PMID 43053549
阅读全文 →
PubMedInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026-11-19

Letter to the Editor: Association between type and duration of menopausal hormone therapy and endometrial cancer risk: A population-based study.

Liu Jingmeng J, Wang Lidong L

PMID 43053522
阅读全文 →
PubMedInternational journal of transgender health2026-11-19

Current status and characteristics of self-medication with gender-affirming hormones among individuals with gender dysphoria in China.

Cai Yueting Y, Chang Xu X, Dong Yulin Y, Li Rucan R et al.

Gender-affirming hormone therapy (GAHT) is an effective treatment for gender dysphoria. However, a substantial proportion of transgender individuals resort to self-medication with hormones. This study aimed to investigate the current status, characteristics, and associated factors of self-medication among individuals with gender dysphoria in China. In this cross-sectional study, data were collected from the Gender Clinic of Peking University Third Hospital between January 2016 and November 2024. Demographic information, hormone treatment history, laboratory test results, scores from the 7-item Generalized Anxiety Disorder Scale (GAD-7), and scores from the 9-item Patient Health Questionnaire (PHQ-9) were analyzed. Among 826 transgender individuals with gender dysphoria, 60.4% had self-medicated before their clinic visit, with 85.4% obtaining hormones from nonmedical sources. The average age at first use was 20.1 years, and the youngest user was 10 years old. The proportion of transgender women was significantly higher in the self-medication group than that in the no self-medication group (90.4% vs. 59.3%, p < 0.001). Multivariate analysis identified being a transgender woman (OR 6.10, 95% CI 4.17-8.95) and the use of psychotropic medications (OR 1.36, 95% CI 1.00-1.86) as independent factors associated with self-medication. No significant differences in GAD-7 or PHQ-9 scores were observed between the two groups. Informal self-medication with GAHT is highly prevalent among transgender individuals in China. Identifying as a transgender woman and using psychotropic medications were independent risk factors associated with self-medication behavior. These findings highlight the need for improved health education and the development of standardized hormone distribution systems to reduce potential risks.

PMID 43053749
阅读全文 →
PubMedNPJ precision oncology2026-11-19

Low-level Aurora kinase A amplification: CDK4/6 inhibitor resistance biomarker in hormone receptor-positive metastatic breast cancer.

Wander Seth A SA, Eli Lisa D LD, Rizvi Ezgi Karaesmen EK, Patel Roosheel Sandeep RS et al.

In this large, real-world, translational research cohort of 708 patients in the Tempus database who had hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) metastatic breast cancer with prior cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) exposure, low-level Aurora kinase A (AURKA) copy-number (CN) gain was common, occurring in 106/708 patients (15.0%). These low-amplification (LA) events impacted RNA expression: patient samples with wild-type AURKA CN had significantly lower median AURKA RNA expression levels than did those with LA or amplified AURKA. Further, LA AURKA CN predicted inferior outcomes on CDK4/6i for patients with HR+, HER2- metastatic breast cancer: real-world progression-free survival was 16.9 months for wild type and 9.3 months for LA AURKA CN (hazard ratio, 1.74; 95% confidence interval, 1.42-2.13; P = 0.0003). These novel results represent the first real-world validation of LA AURKA CN gain as a potential predictor of CDK4/6i resistance.

PMID 43052382
阅读全文 →
PubMedInsect science2026-11-19

The miR-11-3p/SNF axis modulates diet-responsive plasticity in larval molt number in Bombyx mori.

Sun Xiaoning X, Jiang Yanhong Y, Zhang Yi Y, Dai Taiming T et al.

Developmental plasticity enables insects to modify their developmental trajectories in response to environmental fluctuations. Here, we investigated diet-responsive plasticity in larval molt number, or moltinism, using the trimolter (3M) mutant SMJ (Short-instar Millet-yellow Jiangsu) of Bombyx mori. Stage-restricted feeding with old mulberry leaves increased the tetramolter (4M) proportion in SMJ and identified the second larval instar as a major period of dietary sensitivity. Transcriptomic and endocrine analyses revealed differences in cuticle formation and hormone-related processes in SMJ relative to its 4M parent MJ (Millet-yellow Jiangsu). Stage-matched endocrine profiling further showed that key events in the prothoracicotropic hormone-20-hydroxyecdysone axis and juvenile hormone-related processes occurred later in SMJ than in MJ. In SMJ, sustained hormonal perturbation during the second and third larval instars increased the 4M proportion, supporting a link between endocrine timing and moltinism plasticity. Using a robust model of calcium carbonate-induced moltinism shift, midgut small RNA sequencing identified miR-11-3p as a candidate regulator of diet-responsive plasticity in moltinism. Treatment with a miR-11-3p mimic markedly increased the 4M proportion in SMJ, whereas miR-11 knockout increased the 3M proportion in the 4M DaZao background under inductive conditions. Target prediction followed by expression and functional screening prioritized SNF (encoding U1 small nuclear ribonucleoprotein A), whose direct targeting by miR-11-3p was validated by dual-luciferase reporter assays; SNF knockdown phenocopied miR-11-3p mimic treatment by increasing the 4M proportion. Collectively, these findings identify the miR-11-3p/SNF axis as a post-transcriptional regulator that links dietary cues to plasticity in larval molt number.

PMID 43053477
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多parathyroid hormone